1 sustain transmitter release that resulted in muscular weakness.

2 g such as paralysis, movement disorders, and muscular weakness.

3                 Patients develop progressive muscular weakness and atrophy, and no effective therapy

4                                          The muscular weakness and fatigability associated with myast

5 tivation within the spinal cord, accelerated muscular weakness, and a significant decrease in median

6 KO mice showed electrophysiological defects, muscular weakness, and hypersensitivity to mechanical st

7 Follow-up investigations showed a persistent muscular weakness at 60 days, 6 months, and 1 year after

8 (RBM) is a rare disorder causing progressive muscular weakness characterized by aggresome-like inclus

9 LT) of tandutinib was reversible generalized muscular weakness, fatigue, or both, occurring at doses

10                                              Muscular weakness in the first year after transplantatio

11 hic skeletal muscle disease characterized by muscular weakness of proximal dominance, hypotonia, and

12 up of myopathies associated with progressive muscular weakness that are characterized by the presence

13 scle acetylcholine receptor (AChR) cause the muscular weakness that characterizes MG and its animal m